Skip to main content

Applications Of Monoclonal Antibodies

Applications Of Monoclonal Antibodies


What are MAbs made of?

An antibody is a protein that sticks to a specific protein called an antigen. Antibody plays a role circulating throughout the body until it finds the antigen target. 

Monoclonal antibodies are the antibodies that target an antigen, a cancer cell antigen, explicitly. These can be made in laboratories and are said to be monoclonal antibody drugs

These mAbs play a vital role in treating several diseases that include some types of cancers. Monoclonal antibody drugs can be prepared with researchers at work and proven effective against most treatments, including some cancers.

The mAbs are man-made proteins that are similar to human antibodies that form the immune system. There are four ways to make mAbs, and are named on the particular ones as follows: 

  • Murine

These proteins are made via mouse proteins and the names of the treatment associated with this mAb end in -omab.

  • Chimeric

These proteins combine part mouse and part human, with treatment names ending in -ximab.

  • Humanised

When attached to human proteins, these proteins are made out of small parts of the mouse proteins, and this treatment ends in -zumab.

  • Human

These proteins are made from human proteins, and treatment names end with -umab.

Possible side effects of Monoclonal Antibodies

Monoclonal antibodies are injected directly into the vein. The mAbs are themselves proteins and, when injected into the vein, can cause possible allergies or other reactions in the body. There are several potential side effects of monoclonal antibody drugs, as follows: 

    • Fever
    • Chills
    • Weakness
    • Headache
    • Nausea
    • Vomiting
    • Diarrhea
    • Low blood pressure
    • Rashes

These normal reactions are bearable and cured, yet when compared with chemotherapy drugs, the naked mAbs may have some severe side effects. Some monoclonal antibody drugs are specific to the antigen they target for, and they are as follows:

Bevacizumab aka Avastin

It targets the protein called VEGF, affecting the tumour blood vessel growth. This leads to high blood pressure, bleeding and clots, poor wound healing, and kidney damage.

Cetuximab aka Erbitux

This antibody mAb targets a protein called EGFR found on skin cells that may be benign or malignant. This drug can cause severe rashes for some patients.


At GeNext Genomics, we take pride in serving the industry with high-quality monoclonal antibody drugs products and services. With us, we have a team of skilled scientists and experienced professionals at work who cater to all your requirements. They are the reason behind GeNext Genomics to reach research goals and meet quality industry standards.

We believe in building the requirements with precision and top-most accuracy, even creating a humanized monoclonal antibody. We help the industry leaders to achieve their products by using our high-quality molecules. 


Comments

Popular posts from this blog

Unleashing the Power of Recombinant Protein Production with Genext Genomics

Researchers and biotech firms looking for dependable and customizable recombinant protein synthesis services now turn to Genext Genomics as a trusted partner. Genext Genomics is advancing scientific developments and contributing to breakthroughs in drug discovery, biotechnology, and other fields by integrating cutting-edge technologies with a dedication to quality. Work together with Genext Genomics to fully utilize recombinant proteins in your scientific pursuits. Visit Our Website To Get More Information About recombinant protein production service . 

Basic Overview To Recombinant Protein

Recombinant proteins are proteins that are produced using genetic engineering techniques. These techniques involve the insertion of a gene into a host cell, which then expresses the protein encoded by that gene. Recombinant proteins are used in a variety of applications, including drug development, diagnostic testing, and research. Advantage of recombinant proteins is the ability to produce proteins with specific modifications or properties. For example, proteins can be modified to improve their stability, solubility, or activity. This can be particularly useful in drug development, as modified proteins may be more effective or have fewer side effects. There are also some limitations to using recombinant proteins. One potential limitation is the risk of immunogenic reactions, as the host cell used to produce the protein may be foreign to the individual receiving the protein. Recombinant proteins may also require specialized equipment and expertise to produce, which can be costly and ti